GSK plc 6-K, filed Feb 18, 2022
GSK plc (GSK)
6-K
2022-02-18
For: 2022-02-18
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on February 18, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over
Ordinary Shares and American Depositary Shares ('ADSs') made to
Persons Discharging Managerial Responsibilities ('PDMRs') and their
Persons Closely Associated ('PCAs') in 2019 under the
GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were
subject to relevant business performance conditions, and the
subsequent sale of ordinary shares and ADSs to meet tax
liabilities. Awards were made in 2019 and the three-year
performance period commenced on 1 January 2019 and ended on 31
December 2021. The vested shares for the Executive Directors
are now subject to an additional two-year vesting
period.
The performance measure vesting details for those PDMRs who
received awards in 2019 are set out in the following
table.
|
|
Outcome
and Vesting Level
|
||
|
Portion
of the Award
|
Measure
and Outcome
|
% of
maximum
|
% of
award
|
|
1/3rd
|
Adjusted Free Cash Flow - For the three-year period,
the Company achieved Adjusted Free Cash Flow calculated in
accordance with the principles for the measure of £14.53bn,
which is above the level of £13.20bn required for maximum
vesting.
Adjustments
to the original target and vesting schedule were communicated in
the 2020 Annual Report and will be set out in the 2021 Annual
Report.
|
100
|
33.33
|
|
1/3rd
|
Total Shareholder Return - For the three years ending
31 December 2021, the Company's Total Shareholder Return ranked
10th, which is below the threshold vesting level against a
comparator group of 10 global pharmaceutical companies including
GSK.
|
0
|
0
|
|
1/3rd
|
R&D New Products - For the three-year period, the
Company achieved New Product sales calculated in accordance with
the principles for the measure of £11.12bn, which is slightly
below the level of £11.14bn required for 75% vesting.
The threshold vesting level was £10.02bn.
|
74
|
24.66
|
|
|
Total vesting for 2019 award
Lapsed
|
58
42
|
57.99
|
The notifications that follow are for awards made to PDMRs and
their PCAs and detail the PSP conditional awards that vested,
including dividends accrued, on 16 February 2022. The balance
of the award made to each PDMR and PCA has lapsed.
The closing prices of Ordinary Shares and of ADSs of
GlaxoSmithKline plc on the vesting date were £15.76 and
$43.39.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms E Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
274,480
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr I Mackay
|
|||
|
b)
|
Position/status
|
Chief
Financial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
152,815
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr H Barron
|
|||
|
b)
|
Position/status
|
Chief
Scientific Officer and President, R&D
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
|
146,831
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr H Barron
|
|||
|
b)
|
Position/status
|
Chief
Scientific Officer and President, R&D
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share
Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$43.3404
|
79,172
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr R Connor
|
|||
|
b)
|
Position/status
|
President, Vaccines and Global Health
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
119,780
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr R Connor
|
|||
|
b)
|
Position/status
|
President, Vaccines and Global Health
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
56,297
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms D Conrad
|
|||
|
b)
|
Position/status
|
Chief
People Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
Following the vesting on 16 February 2022 of awards granted in
2019 under the Company's 2017 Performance Share Plan, Ms
Conrad will receive a cash payment of £126,710.48 less
applicable tax withholding in respect of 8,006 notional ordinary
shares.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
8,006
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr J Ford
|
|||
|
b)
|
Position/status
|
SVP and
General Counsel
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
|
46,446
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr J Ford
|
|||
|
b)
|
Position/status
|
SVP and
General Counsel
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share
Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$43.3404
|
21,830
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Jackson
|
|||
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
8,006
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Jackson
|
|||
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
3,763
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Jackson
|
|||
|
b)
|
Position/status
|
PCA
of Ms S Jackson (SVP,
Global Communications and CEO Office)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
3,780
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Jackson
|
|||
|
b)
|
Position/status
|
PCA
of Ms S Jackson (SVP,
Global Communications and CEO Office)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
1,777
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr B McNamara
|
|||
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
|
67,075
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr B McNamara
|
|||
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share
Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$43.3404
|
33,974
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr L Miels
|
|||
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
134,163
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr L Miels
|
|||
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
4,008
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Ramakrishnan
|
|||
|
b)
|
Position/status
|
Chief
Technology and Digital Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
|
4,558
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Ramakrishnan
|
|||
|
b)
|
Position/status
|
Chief
Technology and Digital Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share
Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$43.3404
|
2,444
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Redfern
|
|||
|
b)
|
Position/status
|
Chief Strategy Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
110,567
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Redfern
|
|||
|
b)
|
Position/status
|
Chief Strategy Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
51,967
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr R Simard
|
|||
|
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
64,497
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr R Simard
|
|||
|
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
30,314
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr P Thomson
|
|||
|
b)
|
Position/status
|
President,
Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
50,497
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr P Thomson
|
|||
|
b)
|
Position/status
|
President,
Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
23,734
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms D Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
10,978
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms D Waterhouse
|
|||
|
b)
|
Position/status
|
CEO, ViiV Healthcare
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
5,160
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms V Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2019
under the Company's 2017 Performance Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.00
|
8,006
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms V Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2019 under the Company's 2017 Performance
Share Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.8269
|
3,763
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-16
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
18, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|